Psoriasis — SCE Dermatology MCQ

Instant feedback + full explanation. One question, done properly.

HardDermatopharmacologyPsoriasisSCE Dermatology

A 40-year-old woman with psoriasis is considering Brodalumab. What distinguishes Brodalumab from other IL-17 pathway inhibitors?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — It targets the IL-17 receptor A (IL-17RA) rather than the cytokine itself

Brodalumab is unique among IL-17 pathway inhibitors as it targets the IL-17 receptor A (IL-17RA) subunit rather than the IL-17 cytokines themselves. By blocking the receptor, Brodalumab inhibits signalling from IL-17A, IL-17F, IL-17A/F heterodimer, IL-17C, and IL-17E — providing broader IL-17 pathway blockade. Secukinumab and Ixekizumab target IL-17A; Bimekizumab targets IL-17A and IL-17F. Brodalumab carries a black box warning for suicidal ideation and behaviour (based on clinical trial data), requiring REMS programme participation in the US. It has high PASI 100 rates in clinical trials.

Reference: NICE TA511 2018 Brodalumab; BAD 2020 Biologic Guidelines